Histone lactylation facilitates hepatocellular carcinoma progression by upregulating endothelial cell‐specific molecule 1 expression
Molecular Carcinogenesis · 2024-11 · 63 (11) · 2078-2089
DOI: 10.1002/mc.23794 ↗At a glance
Journal article in Molecular Carcinogenesis, published online on 2024-07-17. Written by Peng Zhao and 4 co-authors. Institution: Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Histones, Cell Proliferation. Cited 50 times so far (Crossref); 32 references. Funded by: Clinical Research Project of Taizhou Clinical Medical College of Nanjing Medical University.
Abstract (original language)
Hepatocellular carcinoma (HCC) is a common malignant tumor. Histone lactylation, a novel epigenetic modification, plays a crucial role in various cancers. However, the functional role and underlying mechanism of histone lactylation in HCC progression have not yet been investigated. Histone lactylation levels in HCC tissues and cells were assessed using a densitometric kit and western blot analysis. The role of histone lactylation in cell malignant phenotypes was determined through functional assays in vitro, and a xenograft tumor model was established to verify the function of histone lactylation in vivo. ChIP assay was performed to explore the interaction between histone lactylation and endothelial cell‐specific molecule 1 (ESM1). Additionally, gain‐and‐loss‐of‐function assays were conducted to investigate the regulatory role of ESM1 in HCC pathogenesis. Histone lactylation levels were increased in HCC tissues and cells, and H3K9 lactylation (H3K9la) and H3K56 lactylation (H3K56la) were identified as the histone modification sites. We observed that H3K9la and H3K56la caused abnormal histone lactylation and were associated with poor prognosis. Functionally, histone lactylation was found to promote HCC cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) process in vitro. However, histone lactylation inhibition with 2‐deoxy‐ d ‐glucose (2‐DG) reduced the malignant phenotypes of HCC cells. In vivo, 2‐DG treatment reduced tumor growth and metastasis in the HCC mouse model. Mechanistically, it was revealed that histone lactylation activated ESM1 transcription in HCC cells. ESM1 was expressed at a high level in HCC and exerted a carcinogenic role. Histone lactylation facilitates cell malignant phenotypes, tumor growth, and metastasis by upregulating ESM1 expression in HCC, which reveals the downstream molecular mechanism of histone lactylation and might provide a novel therapeutic target for HCC therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
- Department of Postanesthesia Care Unit, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
Funding
- Clinical Research Project of Taizhou Clinical Medical College of Nanjing Medical University
Cite
APA
Zhao, P., Qiao, C., Wang, J., Zhou, Y., & Zhang, C. (2024). Histone lactylation facilitates hepatocellular carcinoma progression by upregulating endothelial cell‐specific molecule 1 expression. Molecular Carcinogenesis, 63(11), 2078-2089. https://doi.org/10.1002/mc.23794
Vancouver
Zhao P, Qiao C, Wang J, Zhou Y, Zhang C. Histone lactylation facilitates hepatocellular carcinoma progression by upregulating endothelial cell‐specific molecule 1 expression. Molecular Carcinogenesis. 2024;63(11):2078-2089. doi:10.1002/mc.23794
BibTeX
@article{Zhao2024,
author = {Zhao, Peng and Qiao, Chunzhong and Wang, Jiawei and Zhou, Ye and Zhang, Changhe},
title = {Histone lactylation facilitates hepatocellular carcinoma progression by upregulating endothelial cell‐specific molecule 1 expression},
journal = {Molecular Carcinogenesis},
year = {2024},
volume = {63},
number = {11},
pages = {2078--2089},
doi = {10.1002/mc.23794}
}
EUVIMED